MTD Stock Analysis: Mettler-Toledo International | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 26.440m USD | 12M Return: 4.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 249M
EPS Trend: 53.9%
Qual. Beats: 0
Rev. Trend: 50.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Mettler-Toledo International Inc. (MTD) is a Switzerland-based manufacturer of precision instruments and related services, operating through five geographic segments spanning the Americas, Europe, and Asia. The companys product portfolio is organized into three main categories: laboratory instruments (balances, pipettes, titrators, pH meters, thermal analysis systems, and the LabX laboratory software platform), industrial instruments (weighing systems, metal detectors, x-ray systems, checkweighers, and imaging equipment), and retail weighing solutions (including AI-driven image recognition for fresh goods and automated packaging and labeling). Its end markets are diverse, covering pharmaceutical and biotech companies, food manufacturers and retailers, chemical and cosmetics firms, transportation and logistics, metals and electronics, and academic institutions, served through a combination of direct sales and indirect distribution channels.
Although MTD is classified under the GICS Health Care sector within the Life Sciences Tools & Services sub-industry, its business model extends well beyond life sciences into industrial weighing, quality control, and retail automation, giving it a diversified revenue base across multiple end markets. Headquartered in Greifensee, Switzerland, and incorporated in 1991, the company has been listed on the NYSE since 1997.
- China segment weakness pressures organic revenue growth
- Pharma and biotech R&D spending boosts laboratory instrument orders
- Pricing power and buybacks support margin and EPS expansion
| Net Income: 875.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA -5.23 > 1.0 |
| NWC/Revenue: 5.47% < 20% (prev 0.39%; Δ 5.07% < -1%) |
| CFO/TA 0.25 > 3% & CFO 901.1m > Net Income 875.1m |
| Net Debt (2.26b) to EBITDA (1.25b): 1.80 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.3m) vs 12m ago -2.79% < -2% |
| Gross Margin: 57.79% > 18% (prev 58.26%; Δ -0.48% > 0.5%) |
| Asset Turnover: 118.5% > 50% (prev 118.4%; Δ 0.07% > 0%) |
| Interest Coverage Ratio: 16.31 > 6 (EBIT TTM 1.12b / Interest Expense TTM 68.9m) |
| A: 0.06 (Total Current Assets 1.33b - Total Current Liabilities 1.11b) / Total Assets 3.67b |
| B: 2.56 (Retained Earnings 9.41b / Total Assets 3.67b) |
| C: 0.33 (EBIT TTM 1.12b / Avg Total Assets 3.45b) |
| D: -0.01 (Book Value of Equity -41.9m / Total Liabilities 3.71b) |
| Altman-Z'' = 10.93 = AAA |
| DSRI: 1.04 (Receivables 708.2m/638.4m, Revenue 4.09b/3.83b) |
| GMI: 1.01 (GM 58.26% / 57.79%) |
| AQI: 1.03 (AQ_t 0.41 / AQ_t-1 0.40) |
| SGI: 1.07 (Revenue 4.09b / 3.83b) |
| TATA: -0.01 (NI 875.1m - CFO 901.1m) / TA 3.67b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 1296.17 with a total of 80,167 shares traded. Over the past week, the price has changed by -0.94%, over one month by +14.40%, over three months by -2.18% and over the past year by +4.85%.
Current recommended Stop Loss: 1203.30 (which is 7.2% or 2.6 ATR below the current price).
Mettler-Toledo International has received a consensus analysts rating of 3.62. Therefore, it is recommended to hold MTD.
- StrongBuy: 4
- Buy: 0
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 1311.2 | 1.2% |
P/E Trailing = 30.7721
P/E Forward = 28.0112
P/S = 6.4649
P/B = 1328.2277
P/EG = 2.7439
Revenue TTM = 4.09b USD
EBIT TTM = 1.12b USD
EBITDA TTM = 1.25b USD
Long Term Debt = 2.16b USD (from longTermDebt, last quarter)
Short Term Debt = 67.0m USD (from shortTermDebt, last quarter)
Debt = 2.32b USD (from shortLongTermDebtTotal, last quarter) + Leases 88.9m
Net Debt = 2.26b USD (calculated: Debt 2.32b - CCE 60.6m)
Enterprise Value = 28.7b USD (26.4b + Debt 2.32b - CCE 60.6m)
Interest Coverage Ratio = 16.31 (Ebit TTM 1.12b / Interest Expense TTM 68.9m)
EV/FCF = 36.15x (Enterprise Value 28.7b / FCF TTM 793.8m)
FCF Yield = 2.77% (FCF TTM 793.8m / Enterprise Value 28.7b)
FCF Margin = 19.41% (FCF TTM 793.8m / Revenue TTM 4.09b)
Net Margin = 21.40% (Net Income TTM 875.1m / Revenue TTM 4.09b)
Gross Margin = 57.79% ((Revenue TTM 4.09b - Cost of Revenue TTM 1.73b) / Revenue TTM)
Gross Margin QoQ = 58.68% (prev 58.05%)
Tobins Q-Ratio = 7.82 (Enterprise Value 28.7b / Total Assets 3.67b)
Interest Expense / Debt = 2.97% (Interest Expense 68.9m / Debt 2.32b)
Taxrate = 17.18% (181.6m / 1.06b)
NOPAT = 930.5m (EBIT 1.12b * (1 - 17.18%))
Current Ratio = 1.20 (Total Current Assets 1.33b / Total Current Liabilities 1.11b)
Debt / Equity = -55.33 (negative equity) (Debt 2.32b / totalStockholderEquity, last quarter -41.9m)
Debt / EBITDA = 1.80 (Net Debt 2.26b / EBITDA 1.25b)
Debt / FCF = 2.84 (Net Debt 2.26b / FCF TTM 793.8m)
Total Stockholder Equity = -143.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 25.35% (Net Income 875.1m / Total Assets 3.67b)
RoE = -610.3% (negative equity) (Net Income TTM 875.1m / Total Stockholder Equity -143.4m)
RoCE = 55.67% (EBIT 1.12b / Capital Employed (Equity -143.4m + L.T.Debt 2.16b))
RoIC = 36.25% (NOPAT 930.5m / Invested Capital 2.57b)
WACC = 9.16% (E(26.4b)/V(28.8b) * Re(9.75%) + D(2.32b)/V(28.8b) * Rd(2.97%) * (1-Tc(0.17)))
Discount Rate = 9.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -100.00 | Cagr: -2.93%
[DCF] Terminal Value 71.27% ; FCFF base≈823.9m ; Y1≈767.2m ; Y5≈698.9m
[DCF] Fair Price = 369.9 (EV 9.73b - Net Debt 2.26b = Equity 7.48b / Shares 20.2m; r=9.16% [WACC]; 5y FCF grow -8.65% → 2.50% )
EPS Correlation: 53.94 | EPS CAGR: 2.55% | SUE: -0.06 | # QB: 0
Revenue Correlation: 50.89 | Revenue CAGR: 1.56% | SUE: 0.39 | # QB: 0
EPS current Quarter (2026-06-30): EPS=10.80 | Chg30d=+0.15% | Revisions=-42% | Analysts=11
EPS next Quarter (2026-09-30): EPS=12.10 | Chg30d=+0.13% | Revisions=-8% | Analysts=11
EPS current Year (2026-12-31): EPS=46.65 | Chg30d=+0.02% | Revisions=+67% | GrowthEPS=+9.2% | GrowthRev=+5.2%
EPS next Year (2027-12-31): EPS=51.28 | Chg30d=-0.00% | Revisions=+13% | GrowthEPS=+9.9% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +13% (up=24, down=18)